RECRUITING

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.

Official Title

N10: Reduced Therapy for High-Risk Neuroblastoma

Quick Facts

Study Start:2024-07-22
Study Completion:2029-07-22
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06528496

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Months to 19 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of NB as defined by histopathology, BM metastases plus high urine catecholamine levels, or positivity in MIBG scan.
  2. * HR-NB, defined as MYCN-amplified stage L2/M/MS at any age and stage M in patients \>18 months old.
  3. * No more than one prior cycle of HR-NB chemotherapy
  4. * Age \<19 years.
  5. * Signed informed consent indicating awareness of the investigational nature of this treatment.
  1. * Severe dysfunction of major organs, i.e., renal, cardiac, hepatic, neurologic, pulmonary, hematologic, or gastrointestinal toxicity \> grade 2
  2. * Inability to comply with protocol requirements
  3. * Pregnancy

Contacts and Locations

Study Contact

Brian Kushner, MD
CONTACT
8336755491
kushnerb@MSKCC.ORG
Fiorella Iglasias Cardenas, MD, MS
CONTACT
iglesiaf@mskcc.org

Principal Investigator

Brian Kushner, MD
PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering Cancer Center
New York, New York, 10065
United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

  • Brian Kushner, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-07-22
Study Completion Date2029-07-22

Study Record Updates

Study Start Date2024-07-22
Study Completion Date2029-07-22

Terms related to this study

Keywords Provided by Researchers

  • High-risk neuroblastoma
  • neuroblastoma
  • childhood neuroblastoma
  • N10
  • Memorial Sloan Kettering Cancer Center
  • 24-144

Additional Relevant MeSH Terms

  • High-risk Neuroblastoma
  • Neuroblastoma
  • Childhood Neuroblastoma